

Form PTO-1449 (modified)

Atty. Docket No.
4300.014500Serial No./
Unknown 512008**List of Patents and Publications for Applicant's****INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant

Mark A. Atkinson, Sihong Song and Scott A. Loiler

Filing Date:

Concurrently Herewith

Group: 1633**Unknown****U.S. Patent Documents**

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
/SDP/	A1	6,136,597	10/24/00	Hope <i>et al.</i>	435	325	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
/SDP/	B1	WO 99/55564	11/04/99	PCT WIPO	B60S	1708	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/SDP/	C1	PCT Search Report from PCT/US03/12324
	C2	Apparailly <i>et al.</i> , "Tetracycline-Inducible Interleukin-10 Gene Transfer Mediated by an Adeno-Associated Virus: Application to Experimental Arthritis," <i>Human Gene Therapy</i> , 13:1179-88, 2002
	C3	Flotte <i>et al.</i> , "Efficient Ex Vivo Transduction of Pancreatic Islet Cells With Recombinant Adeno-Associated Virus Vectors," <i>Diabetes</i> , 50:515-20, 2001
	C4	Goudy <i>et al.</i> , "Adeno-associated virus vector mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice," <i>PNAS</i> , 98:13913-18, 2001
	C5	Kapturczak <i>et al.</i> , "Adeno-Associated Virus (AAV) as a Vehicle for Therapeutic Gene Delivery: Improvements in Vector Design and Viral Production Enhance Potential to Prolong Graft Survival in Pancreatic Islet Cell Transplantation for the Reversal of Type 1 Diabetes," <i>Current Molecular Medicine</i> , 1:245-58, 2001
	C6	Mah <i>et al.</i> , "Improved Method of Recombinant AAV2 Delivery for Systemic Targeted Gene Therapy," <i>Molecular Therapy</i> , 6:106-12, 2002
	C7	Song <i>et al.</i> , "Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors," <i>Proc. Natl. Acad. Sci. USA</i> , 95:14384-88, 1998
	C8	Song <i>et al.</i> , "Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors," <i>Gene Therapy</i> , 8:1299-306, 2001
↓	C9	Yang <i>et al.</i> , "Suppression of Autoimmune Diabetes by Viral IL-10 Gene Transfer." <i>J. Immunology</i> , 168:6479-85, 2002

EXAMINER: /Scott D. Priebe/**DATE CONSIDERED:** 04/23/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

In place of PTO-1449 Form	U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		<i>Complete if Known</i>																
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 10%;">1</td> <td style="width: 10%;">0</td> <td style="width: 10%;">NOV 11 2005</td> <td style="width: 10%; text-align: right;">1633</td> <td style="width: 40%;"></td> </tr> <tr> <td colspan="2"></td> <td colspan="3" style="text-align: center;">Examiner Name</td> </tr> <tr> <td colspan="2"></td> <td colspan="3" style="text-align: center;">Attorney Docket Number</td> </tr> </table>			1	0	NOV 11 2005	1633				Examiner Name					Attorney Docket Number		
1	0	NOV 11 2005	1633																
		Examiner Name																	
		Attorney Docket Number																	
SHEET	1	0	NOV 11 2005	1633															
				Attorney Docket Number															

FOREIGN PATENT DOCUMENTS					
Examiner's Initials	Cite No.	Foreign Patent Document (Country Code - Number - Kind)	Publication Date MM-DD-YYYY	Patentee or Applicant of Cited Document	Translation Y/N
/SDP/		WO 02/24234 A2	03-28-2002	McGee, et al.	
/SDP/		WO 00/54813 A2	09-21-2000	Manning, et al.	

NON-PATENT LITERATURE DOCUMENTS		
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item, date, page(s), volume-issue number(s), publisher, city/country where published

Examiner Signature	/Scott D. Priebe/	Date Considered	04/23/2007
-----------------------	-------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number		10512008	
	Filing Date		2005-08-11	
	First Named Inventor		Mark A. Atkinson	
	Art Unit		1633	
	Examiner Name		Priebe, Scott David	
	Attorney Docket Number		36689.42	

U.S.PATENTS						Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						
If you wish to add additional U.S. Patent citation information please click the Add button.						Add	
U.S.PATENT APPLICATION PUBLICATIONS						Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						
If you wish to add additional U.S. Published Application citation information please click the Add button.						Add	
FOREIGN PATENT DOCUMENTS						Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1						T ⁵
If you wish to add additional Foreign Patent Document citation information please click the Add button						Add	
NON-PATENT LITERATURE DOCUMENTS						Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>		Application Number	10512008
		Filing Date	2005-08-11
		First Named Inventor	Mark A. Atkinson
		Art Unit	1633
		Examiner Name	Priebe, Scott David
		Attorney Docket Number	36689.42

/SDP/	1	Goudy KS, Wasserfall C, Burkhardt B, Brusko T, Song S, Ellis T, Flotte T, Atkinson MA., Elucidation of Time and Dose Dependencies Using AAV-IL-10 Gene Therapy for Prevention of Type 1 Diabetes in the NOD Mouse. Abstract No. 46. Molecular Therapy. 2002 May;5(5):Part 2 of 2 Parts. S17.	<input type="checkbox"/>
	2	Goudy KS, Burkhardt BR, Wasserfall C, Song S, Campbell-Thompson ML, Brusko T, Powers MA, Clare-Salzler MJ, Sobel ES, Ellis TM, Flotte TR, Atkinson MA., Systemic overexpression of IL-10 induces CD4+CD25+ cell populations in vivo and ameliorates type 1 diabetes in nonobese diabetic mice in a dose-dependent fashion. J Immunol. 2003 Sep 1;171(5):2270-8.	<input type="checkbox"/>
↓	3	Song S, Goudy K, Campbell-Thompson M, Wasserfall C, Scott-Jorgensen M, Wang J, Tang Q, Crawford JM, Ellis TM, Atkinson MA, Flotte TR., Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice. Gene Ther. 2004 Jan;11(2):181-6.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Scott D. Priebe/	Date Considered	04/23/2007
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.